Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
Conditions
Interventions
Pembrolizumab
Locations
59
United States
Moores UC San Diego Cancer Center ( Site 0352)
La Jolla, California, United States
Stanford University Medical Center ( Site 0366)
Palo Alto, California, United States
St. Joseph Heritage Healthcare ( Site 0350)
Santa Rosa, California, United States
Yale University ( Site 0365)
New Haven, Connecticut, United States
Lombardi Comprehensive Cancer Center ( Site 0360)
Washington D.C., District of Columbia, United States
Indiana University Melvin and Bren Simon Cancer Center ( Site 0353)
Indianapolis, Indiana, United States
Start Date
October 26, 2017
Primary Completion Date
July 29, 2020
Completion Date
September 13, 2023
Last Updated
August 23, 2024
NCT07042295
NCT05039801
NCT06980038
NCT04929028
NCT06806852
NCT07403136
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions